RxDoctor Payments Data

Christopher Browning, DPM

Foot & Ankle Surgery · Temple, TXNPI 1255338992

Payments from drug & device makers

$3,569in general payments, 2019–2025

Across 41 payments — averaging $87.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pylant Medical$2K
  • Stryker$558
  • Bone Support Inc.$284
  • Axogen$270
  • Treace Medical Concepts, Inc.$268
  • Integra Lifesciences Corporation$235
  • plus $450 from 7 others

What the payments were for

  • Food & beverage$2,05958%
  • Education$1,51042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,569 in reported general payments places this provider in the 45th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas

Medicare billing

Part B allowed, 2024
$61,361
Medicare patients
294
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole24$27,742
SantylCollagenase Clostridium Hist.14$4,462
Gabapentin69$1,893
Ketoconazole30$822
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip24$501
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen81$454
Doxycycline Monohydrate47$394
Ammonium Lactate15$348
Mupirocin46$331
Ondansetron Hcl45$162
Triamcinolone Acetonide11$77
Oxycodone Hcl13$58
Tramadol Hcl13$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$134$4,46214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 684 foot & ankle surgery providers in Texas.

Other foot & ankle surgery in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →